Curay, the acting director of the FDA’s Center for Drug Evaluation and Research, internally announced her retirement Monday.

Corrigan-Curay has been with the FDA for more than eight years and assumed the acting CDER director role earlier this year after the center's former director, Patrizia Cavazzoni, M.D., stepped ...

It will be co-led by Patrizia Cavazzoni, director of the FDA's Centre for Drugs Evaluation and Research (CDER), and Centre for Biologics Evaluation and Research (CBER) director Peter Marks.

The FDA didn’t routinely test the medications for quality problems or use its vast repository of drug-related complaints to proactively track whether they were harming the people who relied on them.

After Woodcock left her post in 2020 to help lead the agency’s response to the COVID-19 pandemic, the exemptions — including those for Sun and Intas — continued under her successor, Patrizia ...

Corrigan-Curay became CDER’s acting director after former top drug chief, Patrizia Cavazzoni, departed the FDA in January. She previously served as CDER’s principal deputy center director since July ...

Incyte’s Hervé Hoppenot is hanging up his hat after spending more than a decade building the company into the ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

HHS Secretary Robert F. Kennedy Jr. asked the FDA "to review the latest data on mifepristone ," but experts say concerns about the abortion pill's safety are misguided.

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...